Cochrane · systematic review · CD011826
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
van Geffen, WH, Douma, WR, Slebos, DJ, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 20%Low 4 · 80%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: participants with an exacerbation of COPD; people with asthma excluded from our analysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in FEV1 1 h after dosing in ml | no estimate extracted | 1 study · 40 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
Serious adverse events | OR 1 [0.18, 5.53] | 2 studies · 70 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Change in FEV1 closest to 1 h after dosing in ml | no estimate extracted | 4 studies · 126 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Change in dyspnoea score during the first 24 h after dosing | no estimate extracted | 2 studies · 74 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Adverse events/side effects | OR 1.65 [0.42, 6.48] | 3 studies · 110 participants | Low Downgraded: imprecision, inconsistency, indirectness |